CLA (Conjugated Linoleic Acid): The Definitive Guide

What is CLA (Conjugated Linoleic Acid)?

CLA supplements are mixtures of fatty-acid isomers. Pooled weight and body-fat changes are small, and stronger studies weaken the body-fat claim. No U.S. DRI or established requirement exists for supplemental CLA. Food CLA exposure and concentrated isomer blends are different contexts.

Typical CLA (Conjugated Linoleic Acid) Protocols

These rows reproduce sources. Do not average them into one universal regimen.

Which forms and label details matter?

Record total CLA, cis-9/trans-11 and trans-10/cis-12 proportions when stated, carrier oil and co-ingredients. Different isomer blends are not interchangeable.

How should it be stored?

Follow the label, close the container and protect it from heat, light and moisture.

What is it commonly used for?

CLA is marketed for fat loss, lean mass and sports performance. Meta-analyses find small body-composition signals but no reliable weight-loss or performance benefit.

What does human research show?

Asbaghi synthesized 70 randomized trials and 4,159 adults. Pooled reductions were small: about 0.35 kg body weight, 0.44 kg fat mass and 0.77 percentage point body-fat percentage. The high-quality subgroup did not show lower fat mass or body-fat percentage. [1] Liang combined 18 randomized and two crossover exercise trials. CLA plus exercise produced small pooled body-fat and insulin-resistance signals but no weight loss, exercise-performance or lipid benefit; heterogeneity and product variation limit interpretation. [2] These findings do not support describing CLA as an effective stand-alone weight-loss intervention. Official weight-loss guidance likewise treats the evidence and product-safety context cautiously. [3]

How might it act?

Fatty acids enter membranes, serve as energy substrates or act as precursors to mediators according to their structure. This mechanism does not turn a blood-level change into prevention of a clinical event.

How does it compare with related products?

What are the risks and interactions?

GI symptoms can occur. Review diabetes, insulin resistance, liver disease, lipid abnormalities, pregnancy, breastfeeding and multi-ingredient weight-loss stacks. Stop and seek care for jaundice, severe abdominal pain, visual loss or neurologic symptoms.

Which medicines require review?

Have the product reviewed with medicines, before surgery, and during pregnancy or breastfeeding. No universal separation interval is established.

Regulatory status: In the United States, supplements generally lack premarket efficacy approval. In Canada, verify the finished product’s NPN or DIN-HM and licensed conditions. [4], [5]

What should be monitored?

Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, meals, symptoms, medicines, chosen outcome and review date.

What happens when it is stopped?

No ingredient-specific withdrawal syndrome is established. Record the stop date, symptoms and chosen outcome; seek care for a persistent serious symptom.

Seek prompt care for a serious allergic reaction, unusual bleeding, persistent palpitations, chest pain or another severe symptom.

What do public communities report?

Public reports can suggest questions to track, but they do not verify the product, dose or causality. This update did not newly quantify a community sample.

Common questions about CLA (Conjugated Linoleic Acid)

Does CLA cause meaningful weight loss?

Average pooled weight change was small and higher-quality studies weakened body-fat claims.

Does it improve exercise performance?

The current exercise synthesis found no performance benefit.

Are all CLA products equivalent?

No. Isomer proportions and carrier oils differ.

Can I combine it with other weight-loss supplements?

That increases attribution and safety problems; review the entire stack.

Is food CLA the same exposure?

No. Concentrated supplements can use different amounts and isomer ratios.

What should I track?

Total CLA, isomer ratio, administrations, weight, waist, glucose/lipids if relevant, symptoms and review date.

Glossary

Terms for reading the evidence.

ALA

Essential 18-carbon omega-3; adult AIs refer to this form.

EPA

Long-chain omega-3; distinct from total oil weight.

DHA

Long-chain omega-3; often present in a different amount from EPA.

Amount per administration

Amount consumed at one time, distinct from daily total.

Biomarqueur

Biological measure that is not necessarily a clinical benefit.

UL

Tolerable Upper Intake Level established for a nutrient and defined scope.

How this guide was researched

Accessible official sources and human reports were read on October 9, 2026. Titles, authors, journals, DOI, PMID and visible corrections were checked. An unreported frequency was not guessed.

How this guide was made

Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.

Explore the sources